

doi 10.18699/vjgb-26-29

Novel regulatory SNPs that can be activated due to metformin treatment may orchestrate liver gluconeogenesis and add to the variability in AMPK-dependent mechanisms of metformin response

E.E. Korbolina  , I.S. Damarov, T.I. Merkulova 

Institute of Cytology and Genetics of the Siberian Branch of the Russian Academy of Sciences, Novosibirsk, Russia

 lungry@bionet.nsc.ru

Abstract. Metformin is a first-line therapy for type 2 diabetes, yet individual response varies significantly, with over 30 % of patients failing to achieve optimal glycemic control. The specific regulatory mechanisms of this phenomenon remain poorly understood and genetic variants involved are mainly undiscovered. There are multiple lines of evidence that the leading role in determining the variance in phenotypic outcome belongs to regulatory SNPs (rSNPs) as they directly modify gene expression. Therefore, the genome-wide search for such functional variants and deciphering associated phenotypes stands as a fundamental challenge. Previously, based on the results of bioinformatics analysis of allele-specific expression and binding landscape in human peripheral blood mononuclear cells, we have established an original panel of 14 796 rSNPs within promoters of 5132 genes. Aiming to pinpoint functional variants most likely linked to metformin hepatic response and impacts on liver gluconeogenesis, we analyzed the relevant open-access data as well as rSNPs from our panel and the corresponding genes. 1196 genes reported to be regulated by metformin in human hepatocytes and 115 genes involved in gluconeogenesis and/or its regulation via Gene Ontology annotations were intersected. Free R software and STRING v.11 tools were used for functional annotation. A number of genes harboring rSNPs within promoter regions were found to be particularly implicated in the mechanisms of metformin's action. Functional enrichment analyses revealed enrichment in critical pathways including FoxO, TNF- α and TGF- β signaling, also implicated in diabetes complications. Among these, six genes (*ARPP19*, *ATF4*, *NR3C1*, *PFKFB3*, *TCF7L2*, and *WDR5*) were strongly associated with regulation of gluconeogenesis, and may be modulated by metformin in the liver. We conclude that metformin therapy response may be influenced by the newly identified functional SNPs including rSNPs within the promoters of genes for gluconeogenic enzymes and transcription regulators.

Key words: metformin; individual drug response; TD2M; regulatory SNPs; gluconeogenesis; AMPK-dependent mechanisms; signal transduction pathways (FoxO, TNF- α , TGF- β)

For citation: Korbolina E.E., Damarov I.S., Merkulova T.I. Novel regulatory SNPs that can be activated due to metformin treatment may orchestrate liver gluconeogenesis and add to the variability in AMPK-dependent mechanisms of metformin response. *Vavilovskii Zhurnal Genetiki i Seleksii = Vavilov J Genet Breed.* 2026;30(2):259-266. doi 10.18699/vjgb-26-29

Funding. This study was supported by the RSF, Russian Science Foundation (No. 23-15-00113).

Новые регуляторные однонуклеотидные полиморфизмы (rSNPs) потенциально участвуют в регуляции глюконеогенеза в печени и вносят вклад в вариабельность АМФК-зависимых механизмов индивидуального ответа на метформин

E.E. Корболина  , И.С. Дамаров, Т.И. Меркулова 

Федеральный исследовательский центр Институт цитологии и генетики Сибирского отделения Российской академии наук, Новосибирск, Россия

 lungry@bionet.nsc.ru

Аннотация. Метформин является препаратом первого выбора для лечения сахарного диабета второго типа, однако более чем у 30 % пациентов не достигается оптимальный гликемический контроль. Лежащие в основе этого феномена регуляторные механизмы и ассоциированные генетические варианты остаются неизученными. Накопленные данные свидетельствуют о том, что ключевую роль в определении фенотипической вариабельности играют функциональные генетические варианты, в особенности регуляторные однонуклеотидные полиморфизмы (rSNP), непосредственно влияющие на уровень экспрессии генов. Полногеномный поиск таких функциональных вариантов и выявление их фенотипических последствий – актуальная научная задача. Ранее на основе результатов биоинформатического анализа аллель-специфической экспрессии и профиля распределения активирующих гистоновых модификаций в мононуклеарных клетках периферической крови человека нами была сформирована

оригинальная панель из 14796 rSNP, локализованных в промоторах 5132 генов. Целью настоящей работы был поиск в нашей панели rSNP вариантов, потенциально связанных с регуляцией процессов глюконеогенеза в печени, в том числе под действием монотерапии метформином, с помощью анализа независимых релевантных полногеномных данных. Анализировали 1196 генов, экспрессия которых в гепатоцитах человека изменялась под влиянием метформина АМФК-зависимым образом, а также 115 генов, вовлеченных в глюконеогенез и/или его регуляцию, согласно данным генных онтологий. Для функциональной аннотации использовали инструменты свободного программного обеспечения R и базы данных STRING (v.11). В результате анализа был выделен ряд генов, которые, вероятно, играют особую роль в механизмах действия метформина и индивидуальной чувствительности к препарату, в промоторных районах которых нами были картированы rSNP. Функциональный анализ обогащения выявил вовлеченность этих генов в ключевые сигнальные пути, ассоциированные также с осложнениями сахарного диабета второго типа. Для шести генов (*ARPP19*, *ATF4*, *NR3C1*, *PFKFB3*, *TCF7L2* и *WDR5*) экспрессия не только тесно связана с регуляцией глюконеогенеза, но также может модулироваться в гепатоцитах под действием метформина. Мы предполагаем, что rSNP в промоторах генов ферментов, участвующих в глюконеогенезе, и транскрипционных факторов могут играть существенную роль в механизмах формирования индивидуального ответа на терапию метформином.

Ключевые слова: метформин; индивидуальный ответ на препарат; сахарный диабет второго типа; регуляторные полиморфизмы (rSNPs); глюконеогенез; АМФК-зависимая киназа; FoxO, TNF- α , TGF- β -сигнальные пути

Introduction

Metformin, an oral biguanide agent, is the first-line medication to reduce blood glucose levels in patients with T2DM. Although its mechanism of action is still not fully understood, metformin has been shown to decrease liver gluconeogenesis and enhance insulin sensitivity in muscle and adipose tissue (Rena et al., 2017; LaMoia, Shulman, 2021). Moreover, its beneficial pleiotropic effects beyond glycemic control are well known, which include lowering the incidence of cardiovascular events (Bu et al., 2022), correcting energy metabolism in neurologic disorders (Loan et al., 2024), and regulating inflammatory markers (Karbalae-Hasani et al., 2021).

At the molecular level, metformin can inhibit complex I of the mitochondrial electron transport chain in hepatocytes (El-Mir et al., 2000), leading to decreases in ATP and increases in AMP levels and in turn activating AMP-activated protein kinase (AMPK), a master controller of metabolic homeostasis (Smiles et al., 2024). The activation of AMPK results in suppression of gluconeogenic gene expression and reduction in glucose output (LaMoia, Shulman, 2021). Moreover, there is evidence that the metformin glucose-lowering effects in hepatocytes can occur via AMPK-independent mechanisms. In particular, increased AMP levels can directly suppress gluconeogenesis via allosteric inhibition of fructose-1,6-bisphosphatase 1, FBP1 (Hunter et al., 2018). There is also an increasing interest in examining the effects of AMPK activity modulation in chronic metabolic diseases and cancer (Strang et al., 2025), including using the activators and inhibitors with effects independent of AMPK, i. e. compound C, an ATP-competitive AMPK inhibitor (which was reported to disrupt various biological events).

However, metformin's response varies among individuals. As is shown, metformin is ineffective in over 30 % of cases because of various factors, including genetic ones (Cook et al., 2007; St-Amour et al., 2025). Currently, the search for genetic variants (mainly SNPs) associated with drug response efficacy is mainly focused on the genes coding for phase I and II drug metabolizing enzymes, drug transporters, and a number of upstream transcription regulators (Gaedigk et al., 2020; Rykova et al., 2022). Metformin is not metabolized in the human body (Gong et al., 2012); correspondingly, most

studies aimed to identify the SNPs associated with the response to metformin were focused on the genes coding for organic cation transporters (OCTs) and the multidrug and toxin extrusion (MATE) proteins. This allowed for detection of a number of SNPs in the genes of these groups (Zhou et al., 2015; Xiao et al., 2016). The use of unbiased genome-wide approach (GWAS) succeeded in finding several SNPs associated with the response to metformin in genes, the products of which are involved in other functions. These SNPs have been discovered in regulatory regions of the *ATM* gene, the product of which is involved in the maintenance of redox homeostasis in the cell (GoDARTS and UKPDS Diabetes Pharmacogenetics Study Group et al., 2011); the *PRPF31* gene, coding for pre-mRNA processing factor 31; the *CPA6* (carboxypeptidase A6) gene, associated with the regulation of the Akt/mTOR signaling pathway; and the *STAT3* gene, coding for eponymous transcription factor, which is a well-known regulator of metabolic and immune processes (Rotroff et al., 2018).

Nevertheless, GWAS application in pharmacogenomics yet failed to provide a considerable progress, mainly because of the difficulties (and more often, impossibility) in forming large cohorts (tens and hundreds of thousands) of patients to determine the effects of each drug. Modern methods of functional genomics – eQTL analysis and detection of allele-specific events in omics data – do not suffer from this limitation (Degtyareva et al., 2021). However, the studies utilizing these approaches are few and have even absent at all for antidiabetic drugs, including metformin. Earlier, we measured the allelic imbalance at the level of gene expression and the profiles of active chromatin marks in the paired RNA-seq and ChIP-seq data for peripheral blood mononuclear cells (PBMCs) of nine healthy donors and constructed a panel of 14796 regulatory SNPs (rSNPs) potentially able to influence the expression levels of the genes harboring these SNPs in their promoters (Damarov et al., 2024). Then, using the RNA-seq data (GSE153315, GEO DataSets) on the blood cells of T2DM non-responders to metformin ($N = 10$) and T2DM responders ($N = 10$) (Vohra et al., 2022), we found 367 rSNPs from our panel in the promoters of 131 corresponding differentially expressed genes (DEGs). Primary analysis of this gene set revealed a number of transcriptional regulators both known

to be involved in T2DM pathogenesis and still poorly studied (Damarov et al., 2024). Here, we performed further analysis of the obtained rSNP list using independent transcriptomic data on metformin hepatic response (Luizon et al., 2016) and available data on metformin impacts on liver gluconeogenesis.

Materials and methods

Gene sets analyzed. Three original gene sets were compared, and first was the set of 5132 genes harboring the rSNPs in promoter regions based on our previous analysis of allele-asymmetric events in omics data (RNAseq and CHIP-seq) for human PBMCs of nine healthy donors (Damarov et al., 2024). Each rSNP in the reported panel was located within ± 1000 bp from known TSS (transcription start site) and associated with allele-asymmetric binding of activating histone modifications (H3K4me3 and/or H3K27ac, CHIP-seq). Moreover, when analyzing RNA-seq data obtained for the same PBMCs samples, allele-specific expression events were observed within the transcribed sequences of the corresponding genes. Based on the association of the identified regulatory variants with two types of allele-specific events, we assumed that our rSNPs were most likely affecting the expression of certain human genes.

The second gene set comprised 1196 AMPK-dependent genes that were identified through clustering analysis on all DEGs ($p_{adj} < 0.05$) identified from RNA-seq data across the three conditions (treated with metformin, metformin + an AMPK inhibitor (compound C) or no treatment for 8 hours in triplicate) of cultured primary human hepatocytes from a sole male donor (Luizon et al., 2016). The DEGs were termed AMPK-dependent when found differently expressed between hepatocytes with metformin treatment and controls; however, their expression was restored to the normal level (or similarly altered) in hepatocytes with the combined treatment of compound C and metformin. And the third gene set consisted of 115 genes that were classified as involved only in gluconeogenesis, only in regulation of gluconeogenesis, or shared both Gene ontology terms (Ashburner et al., 2000). The analyzed human datasets were under ethical consent agreements as stated in authorized submissions.

Functional annotation. To predict the biological processes and metabolic pathways associated with the analyzed gene lists, a search for associated terms from GO and KEGG gene ontologies and metabolic pathways (Kanehisa, 2000) was performed using the clusterProfiler package (v4.15.1) (Yu et al., 2012) when taking into account the Benjamini–Hochberg correction ($p_{adj} < 0.1$).

A functional protein association network (PPI) was built and analyzed by STRING v.11 tools (Szklarczyk et al., 2023). The k-means clustering was applied in STRING on the basis of evidence score and connection cutoff at 0.40; the enrichments of the KEGG and Wiki pathways were analyzed with a p -value cutoff of < 0.05 and minimum count in the network setting of 2.

Results and discussion

Matching well the generally accepted model for metformin action, our panel of rSNPs located within the promoters of DEGs associated with metformin response (Damarov et al., 2024) included rSNPs within promoters of genes for key

enzymes of mitochondrial electron transfer chain (NDUFA11 and NDUFB1) and upstream/downstream AMPK regulators (Fig. 1). So, AK5 adenylate kinase increases the phosphorylation of AMPK (Dzeja, Terzic, 2009); and N-myristoyltransferase (NMT1) controls the N-myristoylation and lysosomal localization of the AMPK protein (Chen et al., 2020). Activated AMPK inhibits the mTOR (mammalian target of rapamycin) pathway, a pivotal regulator of cell metabolism and growth (Gwinn, Shaw, 2010; Smiles et al., 2024).

To gain a better understanding of the possible involvement of our rSNPs in the mechanisms underlying the antihyperglycemic effects of metformin treatment, we compared and analyzed three gene sets (Fig. 2). The ‘AMPKdep’ set of 1196 AMPK-dependent genes associated with metformin hepatic response was obtained from (Luizon et al., 2016), the ‘rSNPs’ set of 5132 genes with the regulatory variants originally identified within promoter regions was previously reported in (Damarov et al., 2024). Then, the ‘Glu’ set consisted of genes related to gluconeogenesis in GO terms (see the Materials and Methods section for details).

Combining the results of our previous analysis with the AMPKdep gene set allowed to identify 402 genes, the expression of which in hepatocytes may be influenced by our rSNPs. The results of functional enrichment analysis using R signified that Protein processing in endoplasmic reticulum, Apoptosis and FoxO signaling KEGG pathways were enriched in a given set (Fig. 3A). Using the enrichment analysis in STRING, we observed the enrichment of the same gene list belonging to several Wiki metabolic pathways: similarly, apoptosis and, in addition, adipogenesis and signaling pathways including TNF-alpha-, TGF-beta- and angiogenesis-related VEGFA\ VEGFR2-signaling (Fig. 3B).

It is worth to mention that the signaling pathways above were widely reported to be affected by metformin (Yi et al., 2016; Kristófi, Eriksson, 2021; Pan et al., 2024). For example, some mice data indicate the Foxo1 protein to be one of the key targets of metformin in regulating blood glucose and hepatic glucose production under therapeutic concentrations (Guo et al., 2021). Moreover, the same pathways are commonly known as mediators that orchestrate and propagate inflammatory responses and thereby play a crucial role in pathological signaling mechanisms shared among common TD2M complications, including diabetic retinopathy (Behl et al., 2022) and diabetic kidney disease (Ansari et al., 2025; Hou et al., 2025).

When the genes annotated to the ‘Glu’ set were put together with our rSNP panel, we discovered 28 genes in the overlap. The encoded products include important enzymes, i. e. MDH2, malate dehydrogenase 2, which catalyzes a reversible NAD-dependent dehydrogenase reaction and glycolysis enzymes (i. e. ENO1, enolase 1, and PGP, phosphoglycolate phosphatase), as well as a number of regulatory proteins (i. e. FoxO1, USP7, SIRT6). Thus, FoxO1 has a critical role in the insulin-mediated regulation of de novo glucose synthesis affecting the transcription of rate-limiting enzymes, G6Pc and Pck1 (Hall et al., 2014). Notably, multiple studies support that sirtuin 6, SIRT6, an NAD-dependent deacetylase/deacetylase/mono-ADP ribosyltransferase, is involved in inhibition of FoxO1 leading




Fig. 1. Antihyperglycemic effects of metformin are implemented through inhibition of complex I of mitochondrial electron transport chain and activation of AMP kinase. The proteins associated with the AMPK pathway are denoted with blue frames. Green vertical arrows indicate a decrease or an increase in the amount of metabolite or enzyme activity; blunt red arrows indicate inhibition; black arrows indicate membrane transport or a functional connectivity; the complexes of the electron transport chain embedded in the inner mitochondrial membrane are labeled with roman numerals (I through V); NDUFA11, NADH:ubiquinone oxidoreductase subunit A11; NDUFB1, NADH:ubiquinone oxidoreductase subunit B1; AK5, adenylate kinase 5; AMPK, AMP-activated protein kinase; NMT1, N-myristoyltransferase 1; and OCT1, organic cation/carnitine transporter 1.




Fig. 2. Venn diagram representing the intersection between the 'Glu' (orange), 'rSNP' (blue) and 'AMPKdep' (green) gene sets. \cap indicates overlapping; the numerical values in the intersections show the counts for corresponding gene groups.

to suppression of gluconeogenesis (Liu et al., 2021; Wang et al., 2023). Moreover, it was shown that the activation of deubiquitinating enzyme USP7 similarly results in a decrease in FoxO1 activity (Jiang et al., 2017).


Using STRING, we constructed and analyzed a PPI network for this subset of 28 genes (Fig. 4). Three clusters were identified by the KMeans algorithm: nine protein products of

cluster 1 were found to be involved in NADH metabolism and gluconeogenesis; seven from cluster 2, in regulation of gluconeogenesis, circadian rhythms and AMP-activated protein kinase activity (PRKAG2 and PRKACA); and cluster 3 was comprised of two subunits of protein phosphatase 4 complex: PPP4R3A and PPP4R3B (Fig. 4A). It is also to be noted that the protein products of four genes were functionally related to KEGG AMPK-signaling pathway (Fig. 4B). The results of functional enrichment analysis based on Gene Ontology are visualized in Figure 4C.

For a number of these genes, the functional links with regulation of gluconeogenesis have been well described as given on the schematic representation in Figure 5. From this background we hypothesized that our rSNPs located within the corresponding promoters may be involved in regulatory signatures.

Adding the data on AMPK-dependent metformin hepatic response allows us to highlight six genes (*ARPP19*, *ATF4*, *NR3C1*, *PFKFB3*, *TCF7L2*, and *WDR5*) from a list of 28. These genes belong to the intersection of all three compared gene sets, which means the corresponding promoters harbor rSNPs; the genes were shown to be expressed in AMPK-dependent manner in hepatocytes; and the resulting proteins were involved in gluconeogenesis.

Thus, NR3C1, better known as the glucocorticoid receptor (GR), has been functionally linked to stress response, immune regulation, inflammation and control of hepatic gluconeogenesis (Zhang et al., 2019). The encoded protein functions as a transcription factor enhancing the transcription of glu-



A

KEGG ID	Description	FE	p-value	p.Adjust	Count	geneID_symbols
hsa04141	Protein processing in ER	4.13	7.045*e-6	0.0012	14	ATF4/NFE2L2/UBXN4/SEC62/SEC24B/HSPA1B/HSPA1A/PDIA4/RAD23B/UBQLN1/HYOU1/AMFR/PPP1R15A/DNAJC5
hsa04068	FoxO signaling pathway	3.82	2.86*e-4	0.019	10	BCL2L11/PLK2/SGK1/SOD2/CDKN1A/FBXO32/MDM2/GABARAPL1/IRS2/CREBBP
hsa04210	Apoptosis	3.71	3.63*e-4	0.019	10	ATF4/MCL1/CTSS/CFLAR/BCL2L11/DAXX/FAS/FADD/TUBA1B/NFKBIA




Fig. 4. PPI network for the intersection of 28 genes as by STRING. (A) The clusters identified with K-means cluster analysis. (B) Four closely connected PPI members belonging to KEGG AMPK-signaling pathway (hsa04152). (C) A visualization of the most relevant enriched Biological Process Gene Ontology terms. Nodes of different color indicate the members of different clusters (A and B): red – cluster 1, green – cluster 2, and blue – cluster 3. The solid and the dotted lines (A) indicate connections within the same and with a different cluster respectively. Edges of different color indicate both functional and physical protein interactions (A and B): cyan – from curated databases; pink – experimentally determined; blue – gene co-occurrence; khaki – from text mining; black – coexpression; light blue – protein homology. Different enriched terms with corresponding p-values (FDR) are highlighted in different colors according to the color panel (C).




Fig. 5. Multiple potential rSNP targets, including enzymes and regulatory proteins, known to be involved in regulation of gluconeogenesis. Blunt orange arrows indicate the activation of gluconeogenesis and deep-blue ones stand for the suppression of the process; T-shaped blue arrows indicate the suppression of transcription/translation or protein activity; red stars indicate genes from the AMPKdep gene set; AMPK, 5' adenosine monophosphate-activated protein kinase; mTOR, mammalian target of rapamycin; Wnt, Wingless-related integration site; PEPCK, phosphoenolpyruvate carboxykinase; FBP, fructose-1,6-bisphosphatase; F6P, fructose 6-phosphate; F-2,6-BP, fructose-2,6-bisphosphate; NADH, nicotinamide adenine dinucleotide; and NAD⁺, the oxidized form of NAD.

coneogenic genes such as PEPCK and G6Pase under fasting conditions (Beaupere et al., 2021).

ATF4, activating transcription factor 4, is a key protein in metabolic regulation involved in insulin secretion and sensitivity control and regulation of gluconeogenesis by affecting the transcriptional activity of FoxO1 (Li et al., 2022). Interestingly, a number of findings demonstrate epigenetic regulatory mechanisms targeting ATF4. For example, it was reported that microRNA (miR)-214 upregulates ATF4 expression, leading to elevated expression of FoxO1 and thus to suppression of gluconeogenesis (Zhu et al., 2018; Wang et al., 2024).

WRD5 performs multiple scaffolding functions in the context of chromatin and was reported to modulate gluconeogenic gene expression by potentiating the activity of KAT2B histone lysine acetyltransferase. Although these two genes seem to regulate a relatively small subset of gene targets in hepatocytes, both KAT2B and WDR5 are required for the expression of a large fraction of glucagon-inducible genes, indicating that they represent the important cofactors for the CREB pathway (Ravnskjaer et al., 2013).

The TCF7L2 protein is a transcription factor that plays an important role in the Wnt signaling pathway and has been implicated in blood glucose homeostasis (Ip et al., 2012) through actions even beyond pancreatic beta cells (Bailey et al., 2015).

Finally, the protein encoded by *PFKFB3* is a bifunctional enzyme involved in both the synthesis and degradation of fructose-2,6-bisphosphate (F-2,6-BP), and is a potent activa-

tor of 6-phosphofructokinase-1 (PFK-1) – a trigger of aerobic oxidation for glucose metabolism. Recent studies have reported the pivotal role of PFKFB3 in the regulation of insulin resistance (Yang et al., 2023).

Conclusion

This work identifies several novel genes and gene regulatory variants that can be activated due to metformin treatment and thus provides candidates in the human genome where nucleotide variation can lead to differences in metformin response. We conclude that metformin therapy response may depend on the identified functional SNPs within the promoters of genes for gluconeogenic enzymes and regulatory proteins.

Список литературы / References

- Ansari Z., Chaurasia A., Neha, Sharma N., Bachheti R.K., Gupta P.C. Exploring inflammatory and fibrotic mechanisms driving diabetic nephropathy progression. *Cytokine Growth Factor Rev.* 2025;84: 120-134. doi 10.1016/j.cytogfr.2025.05.007
- Ashburner M., Ball C.A., Blake J.A., Botstein D., Butler H., Cherry J.M., Davis A.P., ... Matese J.C., Richardson J.E., Ringwald M., Rubin G.M., Sherlock G. Gene Ontology: tool for the unification of biology. *Nat Genet.* 2000;25(1):25-29. doi 10.1038/75556
- Bailey K.A., Savic D., Zielinski M., Park S.-Y., Wang L., Witkowski P., Brady M., Hara M., Bell G.I., Nobrega M.A. Evidence of non-pancreatic beta cell-dependent roles of Tcf7l2 in the regulation of glucose metabolism in mice. *Hum Mol Genet.* 2015;24(6):1646-1654. doi 10.1093/hmg/ddu577

- Beaupere C., Liboz A., Fève B., Blondeau B., Guillemin G. Molecular mechanisms of glucocorticoid-induced insulin resistance. *Int J Mol Sci.* 2021;22(2):623. doi 10.3390/ijms22020623
- Behl T., Wadhwa M., Sehgal A., Singh S., Sharma N., Bhatia S., Al-Harrasi A., Aleya L., Bungau S. Mechanistic insights into the role of FOXO in diabetic retinopathy. *Am J Transl Res.* 2022;14(6):3584-3602
- Bu Y., Peng M., Tang X., Xu X., Wu Y., Chen A.F., Yang X. Protective effects of metformin in various cardiovascular diseases: Clinical evidence and AMPK-dependent mechanisms. *J Cell Mol Med.* 2022;26(19):4886-4903. doi 10.1111/jcmm.17519
- Chen Y.-C., Navarrete M.S., Wang Y., McClintock N.C., Sakurai R., Wang F., Chen K.T., Chou T.-F., Rehan V.K., Lee D.J., Diaz B. N-myristoyltransferase-1 is necessary for lysosomal degradation and mTORC1 activation in cancer cells. *Sci Rep.* 2020;10(1):11952. doi 10.1038/s41598-020-68615-w
- Cook M.N., Girman C.J., Stein P.P., Alexander C.M. Initial monotherapy with either metformin or sulphonylureas often fails to achieve or maintain current glycaemic goals in patients with Type 2 diabetes in UK primary care. *Diabet Med.* 2007;24(4):350-358. doi 10.1111/j.1464-5491.2007.02078.x
- Damarov I.S., Korbolina E.E., Rykova E.Y., Merkulova T.I. Multi-omics analysis revealed the rSNPs potentially involved in T2DM pathogenic mechanism and metformin response. *Int J Mol Sci.* 2024;25(17):9297. doi 10.3390/ijms25179297
- Deptyareva A.O., Antontseva E.V., Merkulova T.I. Regulatory SNPs: altered transcription factor binding sites implicated in complex traits and diseases. *Int J Mol Sci.* 2021;22(12):6454. doi 10.3390/ijms22126454
- Dzeja P., Terzic A. Adenylate kinase and AMP signaling networks: metabolic monitoring, signal communication and body energy sensing. *Int J Mol Sci.* 2009;10(4):1729-1772. doi 10.3390/ijms10041729
- El-Mir M.-Y., Nogueira V., Fontaine E., Avéret N., Rigoulet M., Leverve X. Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I. *J Biol Chem.* 2000;275(1):223-228. doi 10.1074/jbc.275.1.223
- Gaedigk A., Whirl-Carrillo M., Pratt V.M., Miller N.A., Klein T.E. PharmVar and the landscape of pharmacogenetic resources. *Clin Pharmacol Ther.* 2020;107(1):43-46. doi 10.1002/cpt.1654
- GoDARTS and UKPDS Diabetes Pharmacogenetics Study Group; Wellcome Trust Case Control Consortium 2; Zhou K., Bellenguez C., Spencer C.C., Bennett A.J., Coleman R.L., ... McCarthy M.J., Holman R.R., Palmer C.N., Donnelly P., Pearson E.R. Common variants near *ATM* are associated with glycemic response to metformin in type 2 diabetes. *Nat Genet.* 2011;43(2):117-120. doi 10.1038/ng.735
- Gong L., Goswami S., Giacomini K.M., Altman R.B., Klein T.E. Metformin pathways. *Pharmacogenet Genomics.* 2012;22(11):820-827. doi 10.1097/FPC.0b013e3283559b22
- Guo X., Li X., Yang W., Liao W., Shen J.Z., Ai W., Pan Q., Sun Y., Zhang K., Zhang R., Qiu Y., Dai Q., Zheng H., Guo S. Metformin targets Foxo1 to control glucose homeostasis. *Biomolecules.* 2021; 11(6):873. doi 10.3390/biom11060873
- Gwinn D.M., Shaw R.J. AMPK Control of mTOR signaling and growth. In: Tamanoi F., Hall M.N. (Eds). *The Enzymes*. Vol. 28. Academic Press, 2010;49-75. doi 10.1016/S1874-6047(10)28003-4
- Hall J.A., Tabata M., Rodgers J.T., Puigserver P. USP7 attenuates hepatic gluconeogenesis through modulation of FoxO1 gene promoter occupancy. *Mol Endocrinol.* 2014;28(6):912-924. doi 10.1210/me.2013-1420
- Hou G., Dong Y., Jiang Y., Zhao W., Zhou L., Cao S., Li W. Immune inflammation and metabolic interactions in the pathogenesis of diabetic nephropathy. *Front Endocrinol. (Lausanne).* 2025;16:1602594. doi 10.3389/fendo.2025.1602594
- Hunter R.W., Hughey C.C., Lantier L., Sundelin E.I., Pegg M., Zeqiraj E., Sicheri F., Jessen N., Wasserman D.H., Sakamoto K. Metformin reduces liver glucose production by inhibition of fructose-1-6-bisphosphatase. *Nat Med.* 2018;24(9):1395-1406. doi 10.1038/s41591-018-0159-7
- Ip W., Shao W., Chiang Y.A., Jin T. The Wnt signaling pathway effector TCF7L2 is upregulated by insulin and represses hepatic gluconeogenesis. *Am J Physiol Metab.* 2012;303(9):E1166-E1176. doi 10.1152/ajpendo.00249.2012
- Jiang L., Xiong J., Zhan J., Yuan F., Tang M., Zhang C., Cao Z., ... Wang Hui, Wang L., Wang J., Zhu W.-G., Wang Haiying. Ubiquitin-specific peptidase 7 (USP7)-mediated deubiquitination of the histone deacetylase SIRT7 regulates gluconeogenesis. *J Biol Chem.* 2017; 292(32):13296-13311. doi 10.1074/jbc.M117.780130
- Kanehisa M. KEGG: Kyoto Encyclopedia of Genes and Genomes. *Nucleic Acids Res.* 2000;28(1):2730. doi 10.1093/nar/28.1.27
- Karbalaee-Hasani A., Khadive T., Eskandari M., Shahidi S., Mosavi M., Nejadbrahimi Z., Khalkhali L., Sangdari A., Mohammadi D., Soltani A., Khodabandehloo H., Hosseini H., Koushki M. Effect of metformin on circulating levels of inflammatory markers in patients with type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials. *Ann Pharmacother.* 2021;55(9):1096-1109. doi 10.1177/1060028020985303
- Kristófi R., Eriksson J.W. Metformin as an anti-inflammatory agent: a short review. *J Endocrinol.* 2021;251(2):R11-R22. doi 10.1530/JOE-21-0194
- LaMoia T.E., Shulman G.I. Cellular and molecular mechanisms of metformin action. *Endocr Rev.* 2021;42(1):77-96. doi 10.1210/edrv/bnaa023
- Li J., Yan H., Xiang R., Yang W., Ye J., Yin R., Yang J., Chi Y. ATP secretion and metabolism in regulating pancreatic beta cell functions and hepatic glycolipid metabolism. *Front Physiol.* 2022;13:918042. doi 10.3389/fphys.2022.918042
- Liu G., Chen H., Liu H., Zhang W., Zhou J. Emerging roles of SIRT6 in human diseases and its modulators. *Med Res Rev.* 2021;41(2): 1089-1137. doi 10.1002/med.21753
- Loan A., Syal C., Lui M., He L., Wang J. Promising use of metformin in treating neurological disorders: biomarker-guided therapies. *Neural Regen Res.* 2024;19(5):1045-1055. doi 10.4103/1673-5374.385286
- Luizon M.R., Eckalbar W.L., Wang Y., Jones S.L., Smith R.P., Laurance M., Lin L., ... Molony C., Innocenti F., Yee S.W., Giacomini K.M., Ahituv N. Genomic characterization of metformin hepatic response. *PLoS Genet.* 2016;12(11):e1006449. doi 10.1371/journal.pgen.1006449
- Pan Q., Ai W., Guo S. TGF- β 1 signaling impairs metformin action on glycemic control. *Int J Mol Sci.* 2024;25(4):2424. doi 10.3390/ijms25042424
- Ravnskjaer K., Hogan M.F., Lackey D., Tora L., Dent S.Y.R., Olefsky J., Montminy M. Glucagon regulates gluconeogenesis through KAT2B- and WDR5-mediated epigenetic effects. *J Clin Invest.* 2013;123(10):4318-4328. doi 10.1172/JCI69035
- Rena G., Hardie D.G., Pearson E.R. The mechanisms of action of metformin. *Diabetologia.* 2017;60(9):1577-1585. doi 10.1007/s00125-017-4342-z
- Rotroff D.M., Yee S.W., Zhou K., Marvel S.W., Shah H.S., Jack J.R., Havener T.M., ... Giacomini K.M., Pearson E.R., Wagner M.J., Buse J.B., Motesinger-Reif A.A. Genetic variants in *CPA6* and *PRPF31* are associated with variation in response to metformin in individuals with type 2 diabetes. *Diabetes.* 2018;67(7):1428-1440. doi 10.2337/db17-1164
- Rykova E., Ershov N., Damarov I., Merkulova T. SNPs in 3'UTR mRNA target sequences associated with individual drug susceptibility. *Int J Mol Sci.* 2022;23(22):13725. doi 10.3390/ijms232213725
- Smiles W.J., Ovens A.J., Kemp B.E., Galic S., Petersen J., Oakhill J.S. New developments in AMPK and mTORC1 cross-talk. *Essays Biochem.* 2024;68(3):321-336. doi 10.1042/EBC20240007
- St-Amour S., Tessier L., Harnois J., Allard C., Lavoie A., Caron P., Bouchard L., Perron P., Tremblay K. PCK1 and SLC22A2 gene variants associated with response to metformin treatment in type 2 diabetes. *PLoS One.* 2025;20(2):e0305511. doi 10.1371/journal.pone.0305511

- Strang J., Astridge D., Nguyen V., Reigan P. Small molecule modulators of AMP-Activated Protein Kinase (AMPK) activity and their potential in cancer therapy. *J Med Chem.* 2025;68(3):2238-2254. doi 10.1021/acs.jmedchem.4c02354
- Szklarczyk D., Kirsch R., Koutrouli M., Nastou K., Mehryary F., Hachilif R., Gable A.L., Fang T., Doncheva N.T., Pyysalo S., Bork P., Jensen L.J., von Mering C. The STRING database in 2023: protein-protein association networks and functional enrichment analyses for any sequenced genome of interest. *Nucleic Acids Res.* 2023;51(D1):D638-D646. doi 10.1093/nar/gkac1000
- Vohra M., Sharma A.R., Mallya S., Prabhu N.B., Jayaram P., Nagri S.K., Umakanth S., Rai P.S. Implications of genetic variations, differential gene expression, and allele-specific expression on metformin response in drug-naïve type 2 diabetes. *J Endocrinol Invest.* 2022;46(6):1205-1218. doi 10.1007/s40618-022-01989-y
- Wang Y., Liu T., Cai Y., Liu W., Guo J. SIRT6's function in controlling the metabolism of lipids and glucose in diabetic nephropathy. *Front Endocrinol (Lausanne).* 2023;14:1244705. doi 10.3389/fendo.2023.1244705
- Wang Y., Wang X., Du C., Wang Z., Wang J., Zhou N., Wang B., Tan K., Fan Y., Cao P. Glycolysis and beyond in glucose metabolism: exploring pulmonary fibrosis at the metabolic crossroads. *Front Endocrinol (Lausanne).* 2024;15:1379521. doi 10.3389/fendo.2024.1379521
- Xiao D., Guo Y., Li X., Yin J.-Y., Zheng W., Qiu X.-W., Xiao L., Liu R.-R., Wang S.-Y., Gong W.-J., Zhou H.-H., Liu Z.-Q. The impacts of *SLC22A1* rs594709 and *SLC47A1* rs2289669 polymorphisms on metformin therapeutic efficacy in chinese type 2 diabetes patients. *Int J Endocrinol.* 2016;2016:4350712. doi 10.1155/2016/4350712
- Yang Q., Huo E., Cai Y., Zhang Z., Dong C., Asara J.M., Wei Q. PFKFB3-mediated glycolysis boosts fibroblast activation and subsequent kidney fibrosis. *Cells.* 2023;12(16):2081. doi 10.3390/cells12162081
- Yi Q.-Y., Deng G., Chen N., Bai Z.-S., Yuan J.-S., Wu G.-H., Wang Y.-W., Wu S.-J. Metformin inhibits development of diabetic retinopathy through inducing alternative splicing of VEGF-A. *Am J Transl Res.* 2016;8(9):3947-3954
- Yu G., Wang L.-G., Han Y., He Q.-Y. clusterProfiler: an R package for comparing biological themes among gene clusters. *Omi A J Integr Biol.* 2012;16(5):284-287. doi 10.1089/omi.2011.0118
- Zhang X., Yang S., Chen J., Su Z. Unraveling the regulation of hepatic gluconeogenesis. *Front Endocrinol (Lausanne).* 2019;9:802. doi 10.3389/fendo.2018.00802
- Zhou Y., Ye W., Wang Y., Jiang Z., Meng X., Xiao Q., Zhao Q., Yan J. Genetic variants of OCT1 influence glycemic response to metformin in Han Chinese patients with type-2 diabetes mellitus in Shanghai. *Int J Clin Exp Pathol.* 2015;8(8):9533-9542
- Zhu X., Li H., Wu Y., Zhou J., Yang G., Wang W. lncRNA MEG3 promotes hepatic insulin resistance by serving as a competing endogenous RNA of miR-214 to regulate ATF4 expression. *Int J Mol Med.* 2018;43(1):345-357. doi 10.3892/ijmm.2018.3975

Conflict of interest. The authors declare no conflict of interest.

Received October 17, 2025. Revised November 21, 2025. Accepted December 1, 2025.